Your browser doesn't support javascript.
loading
First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆.
Niu, J; Maurice-Dror, C; Lee, D H; Kim, D-W; Nagrial, A; Voskoboynik, M; Chung, H C; Mileham, K; Vaishampayan, U; Rasco, D; Golan, T; Bauer, T M; Jimeno, A; Chung, V; Chartash, E; Lala, M; Chen, Q; Healy, J A; Ahn, M-J.
Afiliação
  • Niu J; Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, USA. Electronic address: jiaxin.niu@bannerhealth.com.
  • Maurice-Dror C; Medical Oncology Division, Rambam Health Care Campus, Haifa, Israel.
  • Lee DH; Department of Oncology, Asan Medical Center, Seoul, South Korea.
  • Kim DW; Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea.
  • Nagrial A; Medical Oncology, Blacktown Hospital, Blacktown, Australia; Medical Oncology, University of Sydney, Sydney, Australia.
  • Voskoboynik M; Alfred Health and Monash University, Melbourne, Australia.
  • Chung HC; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
  • Mileham K; Levine Cancer Institute, Atrium Health, Charlotte, USA.
  • Vaishampayan U; Oncology/Internal Medicine, Karmanos Cancer Center, Detroit, USA.
  • Rasco D; START Center for Cancer Care, San Antonio, USA.
  • Golan T; The Oncology Institute, Sheba Medical Center at Tel-Hashomer, Tel Aviv University, Tel Aviv, Israel.
  • Bauer TM; Drug Development, Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, USA.
  • Jimeno A; Medicine, University of Colorado, Anschutz Cancer Pavilion, Aurora, USA.
  • Chung V; Medical Oncology, City of Hope National Medical Center, Duarte, USA.
  • Chartash E; Oncology Early Development, Merck & Co., Inc., Kenilworth, NJ, USA.
  • Lala M; OED-QP2IO, Merck & Co., Inc., Kenilworth, NJ, USA.
  • Chen Q; BARDS, Merck & Co., Inc., Kenilworth, NJ, USA.
  • Healy JA; Oncology Early Development, Merck & Co., Inc., Kenilworth, NJ, USA.
  • Ahn MJ; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Ann Oncol ; 33(2): 169-180, 2022 02.
Article em En | MEDLINE | ID: mdl-34800678
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article